An Observational Study of Patients With Chronic Kidney Disease

Overview

TARGET-KIDNEY is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESKD).

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Other
• Study Primary Completion Date: December 2037

Interventions

• Other: Observational
  • Observational

Arms, Groups and Cohorts

• Disease Cohort
• Engaged Cohort

Clinical Trial Outcome Measures

Primary Measures

• To characterize the natural history of disease in patients with CKD/ESKD
  • Time Frame: 20 Years
• To assess safety and effectiveness of CKD/ESKD treatments and treatments for complications of either condition
  • Time Frame: 20 Years

Secondary Measures

• To evaluate provider management practices in the treatment of patients with CKD/ESKD
  • Time Frame: 20 Years
• To evaluate longitudinal and patient reported outcomes in CKD/ESKD
  • Time Frame: 20 Years
• To select and evaluate quality of care measures for patients with CKD/ESKD
  • Time Frame: 20 Years

Participating in This Clinical Trial

Disease Cohort Inclusion Criteria:

• Adult* patients at the time of enrollment with a diagnosis of CKD/ESKD by ICD-10 code in the EHR interface Exclusion Criteria:

• Death – Manual removal (sponsor or site request) – No EHR interface encounter > 3 years Engaged Cohort Inclusion Criteria:

• Adult * patients diagnosed and managed for CKD/ESKD invited to participate – Ability to provide written informed consent Exclusion Criteria:

• Patient expressed desire to withdraw consent to complete PROs – Failure to complete PROs within 24 weeks of initial invitation – Greater than 24 months lapse of survey completion after baseline surveys completed – Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

• Lead Sponsor
  • Target PharmaSolutions, Inc.
• Provider of Information About this Clinical Study
  • Sponsor